7:00 AM – 7:30 AM Breakfast and Registration
7:30 AM – 7:45 AM Welcome, Introduction, and Baseline Assessment
7:45 AM – 8:15 AM Clinical Discussion: When and How to Assess Genomic and Molecular Alterations in AML: Which Mutations Matter
8:15 AM – 8:45 AM Available and Emerging Treatment Options in FLT3-Mutant AML
8:45 AM – 9:15 AM Available and Emerging Treatment Options in IDH-Mutant AML
9:15 AM – 9:45 AM Overcoming Treatment Challenges in AML With New Targeted Agents and Formulations
9:45 AM – 10:15 AM New Advances in Antibody–Drug Conjugates and Other Immunotherapeutic Agents
10:15 AM – 10:30 AM Final Thoughts and Take-home Conclusions From the Program Director
Eunice S. Wang, MD
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Amir T. Fathi, MD
Associate Professor of Medicine, Harvard Medical School
Program Director, Center for Leukemia Massachusetts General Hospital
Jeffrey E. Lancet, MD
Senior Member & Professor
Chair, Department of Malignant Hematology
Moffitt Cancer Center
Farhad Ravandi, MD
Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.
This program is intended for physicians, nurses, pharmacists, physician assistants, and other healthcare providers who treat and manage patients with AML.
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
- Plan evidence-based therapeutic strategies using novel targeted agents or formulations and refinements of conventional chemotherapy
- Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody-based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell-based therapy
- Manage treatment-related toxicities associated with novel therapeutics
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
NCCN designates this educational activity for a maximum of 3.0 contact hours.
Pharmacist Continuing Education
NCCN designates this application-based continuing education activity for 3.0 contact hours (0.3 CEUs) of continuing education credit. UAN: JA4008196-9999-19-070-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.